



IG-001
由智新生技研發
針對新冠肺炎的siRNA基因治療藥物

經濟損失:
COVID-19 大流行全球已造成超過 20 兆美元的重大經濟損失。
缺乏有效治療:
對於 COVID-19 仍然缺乏強力有效的治療方法,尤其病毒不斷的更新病毒碼,持續對人類健康造成威脅。
人們對疫苗的猶豫不決:
儘管已經推出了 mRNA 疫苗,但許多民眾仍然存在對施打疫苗與否的信任度問題。

siRNA創新解決方案:
目前,美國FDA已經批准了數種用於治療COVID-19的藥物,包括抗病毒藥物、免疫調節劑和腎功能替代療法。
由智新生技開發的IG-001 為使用siRNA基因編碼方式對抗COVID病毒的核酸藥物,預期將能對已知病毒及其未知的潛在變異體實現精確的針對性治療。

IG-002
由智新生技研發
針對流行性感冒病毒開發的siRNA基因治療藥物

高發生率和嚴重性:
流感仍然是一個重大的世界公共衛生挑戰,每年全球約有10億例病例,其中包括300萬至500萬嚴重病例和數十萬例相關的呼吸道死亡。
新興的流行性威脅:
日前科學家發布了涉及禽流感毒株的實驗室測試,對於潛在大規模傳染病或大流行感染提出警告,這凸顯了流感病毒不斷演變的特點,以及從動物傳染至人類的重大健康威脅。

先進藥物開發:
智新生技擁有針對病毒演化中的一個保守區域設計siRNA的領先技術,我們研發的新藥IG-002預期能引領先進流感藥物的開發。
更加廣泛且精確的解決方案:
IG-002 能夠提供針對所有已知和潛在的流感病毒進行基因編碼解譯,開發更全面且精確的核酸治療藥物。
“We found that the administration and access to vaccine were some of the major concerns. While most of the information was received from the internet, they were not directly obtained from the health organization. Misinformation may cause negative emotions. In some cases, conspiracy spreading in social media may cause substantial amount of fear.” – “Topics and Sentiments of Public Concerns Regarding COVID-19 Vaccines: Social Media Trend Analysis”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534488/
“the COVID-19 pandemic remains a high priority for the Center for Drug Evaluation and Research (CDER). CDER will remain engaged with numerous activities to protect and promote public health.”
https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs
“Influenza is a serious global health threat that impacts all countries: every year, up to 650 000 people die of respiratory diseases related to seasonal influenza.” –WHO website “Influenza is on the rise”
https://www.who.int/news/item/01-10-2021-influenza-is-on-the-rise-how-do-i-prevent-it
British Daily Mail “Bird flu strain in China has 'pandemic potential', scientists warn”
https://www.msn.com/en-au/health/health-newsbird-flu-strain-in-china-has-pandemic-potential-scientists-warn/